EQRx Revises Plans To Get Chinese Licensed Drugs To US Market

 
• By Jessica Merrill

The company has filed its first drug in the UK and initiated a US-based Phase III trial; US drug pricing legislation underscores the company's value proposition, CEO argues, since payers will still be under pressure.

U turn
EQRx is changing development plans for two drugs licensed from Chinese partners. • Source: Shutterstock

More from Clinical Trials

More from R&D